UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of May 2018

 

001-37353

(Commission File Number)

 

BIONDVAX PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

 

14 Einstein St.

Ness Ziona

Israel 7414002

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ☐     No ☒

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A

 

 

 

 

 

 

Financial Statements for the period ending on March 31, 2018

  

On May 29, 2018, BiondVax Pharmaceuticals Ltd. (“BiondVax”) issued a press release announcing its financial results for the period ended March 31, 2018. A copy of this press release and interim unaudited financial statements for period ended March 31, 2018, are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference. 

 

Compensation to Audit Committee members

 

On May 28, 2018, the compensation committee and the board of directors approved and ratified the compensation to all members of the audit and compensation committees, Ms. Michal Marom Brikman, Dr. Ruth Ben Yakar and Dr. Morris Laster, in accordance with the Israeli Companies Law (Rules Regarding Compensation and Expenses to External Director)- 2000-5760. Accordingly, Ms. Brikman, Dr. Ben Yakar and Dr. Laster shall be entitled to receive the minimum annual and participatory compensation, equal to NIS 21,425 per year and NIS 620 per meeting, respectively.

 

Exhibit Index

 

Exhibit No.   Description
     
99.1   Press Release dated May 29, 2018.
99.2   BiondVax Pharmaceuticals Ltd. unaudited financial statements for the period ended March 31, 2018.

  

  1  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BiondVax Pharmaceuticals Ltd.
     
Date: May 29, 2018 By: /s/ Ron Babecoff
    Ron Babecoff
    Chief Executive Officer

 

 

2

 

BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more BiondVax Pharmaceuticals Charts.
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more BiondVax Pharmaceuticals Charts.